First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Soria J.-C.Tan D.S.W.Chiari R.Wu Y.-L.Paz-Ares L.Wolf J.Geater S.L.Orlov S.Cortinovis D.CHONG-JEN YUHochmair M.Cortot A.B.Tsai C.-M.Moro-Sibilot D.Campelo R.G.McCulloch T.Sen P.Dugan M.Pantano S.Branle F.Massacesi C.de Castro G.Jr2022-06-272022-06-2720170140-6736https://www.scopus.com/inward/record.uri?eid=2-s2.0-85010189205&doi=10.1016%2fS0140-6736%2817%2930123-X&partnerID=40&md5=d0a7d90ac9d7d8a54ee8779e0f5dce70https://scholars.lib.ntu.edu.tw/handle/123456789/614109[SDGs]SDG3First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 studyjournal article10.1016/S0140-6736(17)30123-X281263332-s2.0-85010189205